BD Molecular Diagnostics

BD MAX™ GBS

ELEVATE THE STANDARD OF CARE FOR GBS

Group B streptococcal (GBS) disease is a leading infectious cause of morbidity and mortality among newborns in the United States.1 More than 60% of term infants with GBS disease were born to women who had tested negative for GBS by way of non-molecular methods before delivery.2 Approximately 10% to 30% of pregnant women are colonized with GBS in the vagina or rectum, and GBS colonized women are >25 times more likely to deliver infants with early-onset GBS disease.3 For laboratories performing conventional culture, sensitivity of these tests can be as low as 42% with turn-around times as long as 3 to 4 days.4 Real-time PCR following Lim Broth enrichment provides rapid identification and the highest level of sensitivity for detection of GBS.5

INTRODUCING BD MAX™ GBS

BD MAX GBS is a fully-automated, real-time PCR method for the detection of GBS from enriched culture. It simplifies detection of GBS colonization in antepartum pregnant women, and rapidly identifies Group B Streptococcus after an overnight Lim Broth enrichment.

Visit BD Molecular Diagnostics for detailed information on BD MAX GBS (Cat No. 441772).


REFERENCES

  1. MMWR August 15, 2002/51(RR11); 1-22
  2. Van Dyke et al., N Engl J Med 2009;360:2626-36
  3. Verani JR, McGee L, Schrag G; Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1-32.
  4. Montague et al., J Clin Micro 2008;46:3470-3472
  5. Miller et al., J Clin Micro 2015; 53:1938-1941

Request Information